Evidence-Based Reviews

Perimenopausal depression: Covering mood and vasomotor symptoms

Current Psychiatry. 2008 October;7(10):39-50

References

1. Schmidt PJ, Rubinow DR. Reproductive ageing, sex steroids and depression. J Br Menopause Soc 2006;12(4):178-85.

2. Rasgon N, Shelton S, Halbreich U. Perimenopausal mental disorders: epidemiology and phenomenology. CNS Spectr 2005;10(6):471-8.

3. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29(1):25-31.

4. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54(5):573-83.Erratum in: Biol Psychiatry. 2003;54(5):585.

5. Feld J, Halbreich U, Karkun S. The association of perimenopausal mood disorders with other reproductive-related disorders. CNS Spectr 2005;10(6):461-70.

6. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56.

7. Campbell S, Whitehead M. Oestrogen therapy and the menopause syndrome. Clin Obstet Gynecol 1977;4:31-47.

8. Schmidt PJ, Rubinow DR. Menopause-related affective disorders: a justification for further study. Am J Psychiatry 1991;48:844-52.

9. Soares CN. Menopausal transition and depression: who is at risk and how to treat it? Expert Rev Neurother 2007;7(10):1285-93.

10. Prior JC. The complex endocrinology of menopausal transition. Endocrinol Rev 1998;19:397-428.

11. Rasgon N, Altshuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002;63(suppl):45-8.

12. Altshuler LL, Cohen LS, Moline ML, et al. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad Med 2001 Mar;(Spec No):1-107.

13. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.

14. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

15. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-93.

16. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2947-58.

17. Shumaker SA, Legault C, Rapp SR. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.

18. FDA approves new labeling and provides new advice to postmenopausal women who use or who are considering using estrogen and estrogen with progestin [FDA Fact Sheet January 8, 2003]. Available at: http://www.fda.gov/oc/factsheets/WHI.html. Accessed September 11, 2008.

19. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13(5):780-6.

20. Cohen LS, Soares CN, Joffe H. Diagnosis and management of mood disorders during the menopausal transition. Am J Med 2005;118(suppl 12B):93-7.

21. Kahn DA, Moline ML, Ross RW, et al. Depression during the transition to menopause: a guide for patients and families. Postgrad Med 2001 Mar;(Spec No):110-1.

22. Alder J, Besken KE, Armbruster U, et al. Cognitive-behavioural group intervention for climacteric syndrome. Psychother Psychosom 2006;75(5):298-303.

23. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58(6):529-34.

24. Otto MW, Smits JA, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice 2005;12:72-86.

25. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord 2000;60:121-30.

26. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry [American Psychiatric Association subcommittee report]. J Clin Psychiatry 2006;67:1954-67.

27. Otto MW, Church TS, Craft LL, et al. Exercise for mood and anxiety disorders. J Clin Psychiatry 2007;68:669-76.